What Are Lysosomes and Why Your Cells Need Them

The Cell's Recycling Center

Deep inside every human cell sits a tiny, acid-filled compartment that keeps the entire operation running. Lysosomes — from the Greek lysis (loosening) and soma (body) — are membrane-bound organelles that act as the cell's recycling centers. They break down worn-out proteins, damaged organelles, invading bacteria, and other cellular debris into reusable building blocks like amino acids, sugars, and fatty acids.

First described by Belgian biochemist Christian de Duve in 1955 — a discovery that earned him the 1974 Nobel Prize in Physiology or Medicine — lysosomes were long dismissed as simple "trash bags." Scientists now recognize them as sophisticated signaling hubs that regulate metabolism, immune defense, and even how cells decide to live or die.

How Lysosomes Work

Each lysosome contains roughly 60 different digestive enzymes, including proteases, lipases, and glycosidases. These enzymes require an acidic environment — around pH 4.5 to 5.0 — to function, which is why the lysosome pumps protons across its membrane to maintain acidity far below the cell's neutral interior.

Material reaches lysosomes through several pathways. During autophagy — a term de Duve himself coined — cells package damaged organelles or misfolded proteins into double-membraned vesicles that fuse with lysosomes for digestion. Foreign invaders like bacteria arrive via endocytosis, engulfed by the cell membrane and delivered to lysosomes for destruction. The breakdown products are then exported back into the cell to fuel energy production or build new molecules.

Recent research has revealed that lysosomes also act as nutrient sensors. When nutrients are abundant, lysosomes activate a protein complex called mTORC1, which promotes cell growth. When nutrients are scarce, lysosomes suppress mTORC1 and ramp up autophagy — effectively telling the cell to recycle its own components for survival.

When the Recycling System Breaks Down

If a lysosomal enzyme is missing or defective, undigested material accumulates inside cells like garbage piling up in a factory. This causes a group of more than 70 rare inherited conditions collectively known as lysosomal storage diseases (LSDs). Though each individual disorder is rare, together they affect roughly 1 in 5,000 live births, according to the Cleveland Clinic.

Among the best-known LSDs are Gaucher disease, where fatty substances accumulate in organs and bones, and Tay-Sachs disease, where nerve cells in the brain are progressively destroyed. Many of these conditions appear in infancy or early childhood and can be fatal without treatment.

But lysosomal dysfunction extends well beyond rare diseases. Impaired lysosomal clearance contributes to the buildup of toxic protein aggregates in Alzheimer's disease (amyloid-beta and tau) and Parkinson's disease (alpha-synuclein). A March 2026 study published in PNAS identified a critical lysosomal ion channel called TMEM175 that acts as an "overflow valve," regulating acid levels inside lysosomes. When this channel is faulty, lysosomes become too acidic, their enzymes malfunction, and alpha-synuclein accumulates — accelerating neurodegeneration.

Treatments and Future Directions

For lysosomal storage diseases, enzyme replacement therapy (ERT) remains the most established treatment. Patients receive regular infusions of the missing enzyme, though the therapy is lifelong and expensive. Eight LSDs currently have approved ERTs, including Gaucher and Fabry diseases.

Other approaches include substrate reduction therapy, which slows the production of the material that accumulates, and gene therapy, which aims to correct the underlying genetic defect. Researchers are also investigating pharmacological chaperones — small molecules that stabilize faulty enzymes so they can still function partially.

The TMEM175 discovery has opened yet another avenue: scientists identified existing drugs, including the asthma medication montelukast, that can activate the faulty ion channel. If these findings translate to clinical trials, repurposing an already-approved drug could dramatically accelerate treatment timelines for Parkinson's patients.

Why Lysosomes Matter More Than Ever

As populations age, diseases linked to lysosomal dysfunction — Alzheimer's, Parkinson's, and age-related metabolic decline — are becoming an ever-larger public health burden. Understanding these tiny organelles is no longer a niche pursuit in cell biology. It is central to tackling some of the most devastating conditions of the modern era.